GBI Research

Global Viral Infections Market to 2021 – Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics $4995

Global Viral Infections Market to 2021 – Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics Summary Viruses are infectious particles comprising a nucleic acid core ...Read the full article

5th April, 2016 • GBI Research

 

Frontier Pharma: Schizophrenia and Associated Indications – Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms $6995

Frontier Pharma: Schizophrenia and Associated Indications – Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a severe mental ...Read the full article

1st April, 2016 • GBI Research

 

Global Non-Hematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics $4995

Global Non-Hematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics Summary In 2012, there were 32.6 million people living ...Read the full article

1st April, 2016 • GBI Research

 

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies $4995

Alzheimer’s Disease Market in Asia-Pacific to Surpass $5 Billion by 2021, says GBI Research The Asia-Pacific (APAC) Alzheimer’s disease market will grow from $3 billion in 2014 to $5.1 billion in 2021, representing a robust Compound Annual Growth Rate of 7.9%, according to business intelligence provider GBI Research. Latest report* states that the main driver of this impressive growth, which will occur across the APAC countries of India, China, Australia and Japan, will be rising and aging populations, as Alzheimer’s disease is significantly more prevalent among the elderly.

1st March, 2016 • GBI Research

 

Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns $4995

Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns Summary Asthma is a common chronic ...Read the full article

1st March, 2016 • GBI Research

 

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes $6995

Breast Cancer is Only Pharmaceutical Pipeline with over 1000 Drugs in Development, says GBI Research The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.

16th February, 2016 • GBI Research

 

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments $4995

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments Summary Parkinson’s Disease (PD) is a ...Read the full article

11th February, 2016 • GBI Research

 

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence $4995

APAC Breast Cancer Market Will Rise Substantially to $3.4 Billion by 2021, says GBI Research The Asia-Pacific (APAC) breast cancer market is set to experience considerable expansion from $1.9 billion in 2014 to $3.4 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 8.5%, according to business intelligence provider GBI Research. Such growth, which will occur across the APAC regions of India, China, Australia, and Japan, will be driven by aging populations, changing lifestyle habits, improved survival rates, and a number of new approvals for drugs that are expected to supplement current market leaders.

4th February, 2016 • GBI Research

 

Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 – Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents $4995

Alzheimer’s Disease Market Will More Than Double to $10.4 Billion by 2021, says GBI Research The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11%, according to business intelligence provider GBI Research. Mushtaq comments: “The fact that people are living longer across the globe means more cases of the disease are developing, and this has posed a growing public health crisis, which represents a very serious disease burden for patients and carers alike.

1st February, 2016 • GBI Research

 

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth $4995

Asia-Pacific Type 2 Diabetes Mellitus Treatment Market Will Exceed $10 Billion by 2021, says GBI Research The treatment market for Type 2 Diabetes Mellitus (T2DM) in the Asia-Pacific (APAC) region will increase from a little under $6.1 billion in 2014 to just over $10 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.7%, according to business intelligence provider GBI Research. Substantial growth, which will occur across the countries of China, India, Japan and Australia, will be driven by the rapidly expanding prevalence population resulting from increasingly aging populations and sedentary lifestyles. Higher diagnosis and treatment rates, due to rising disease awareness among the public, will also play a role.

1st January, 2016 • GBI Research

 

Frontier Pharma: Parkinson’s Disease – Identifying and Commercializing First-in-Class Innovation $6995

Parkinson’s Disease Treatment Pipeline Holds Significant Potential for Patients and Investors, says GBI Research The Parkinson’s disease treatment pipeline presents a distinctly more promising landscape than the current market, which is burdened with unmet needs and a lack of disease-modifying drugs, says business intelligence provider GBI Research. According to the company’s latest report*, the current Parkinson’s disease treatment market relies on neuromodulators, and although levodopa and dopaminergic treatments can be used to relieve symptoms, there is not an agent that has demonstrated neuroprotective properties to prevent or at least significantly slow neuronal cell death.

1st January, 2016 • GBI Research

 

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 – Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line $4995

Description Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced ...Read the full article

18th December, 2015 • GBI RESEARCH

 

Frontier Pharma: Ovarian Cancer – Identifying and Commercializing First-in-Class Innovation

Description Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although ...Read the full article

12th December, 2015 • GBI RESEARCH

 

Myeloma Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments $4995

Description: Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have ...Read the full article

22nd October, 2015 • GBI RESEARCH

 

Opioids Market to 2018 – Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market $3500

Opioids Market to 2018 – Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market Summary Leading business intelligence provider GBI Research has released its latest research ...Read the full article

4th January, 2013 • GBI Research

 

Let’s get started...

Broker Rating Markets Available Fees Open an Account
Kawase Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 3.60 /5
(15 votes cast)
Loading...
Shares, Indices, Forex and Oil Spread From 0.1 and 0.2% Commission Visit Website
Plus500 Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.48 /5
(452 votes cast)
Loading...
Stocks, Commodities, Indices and Forex. Zero commissions. No monthly fees. $10 USD fee for unused account for a period of three months. Visit Website
MaxFx Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.70 /5
(89 votes cast)
Loading...
Indices, Forex, Metals, Shares From 0.1 Raw Interbank Spread Visit Website
Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.